Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05059873
Other study ID # Z201100005520029
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date March 5, 2023
Est. completion date March 31, 2024

Study information

Verified date March 2023
Source Capital Medical University
Contact Rong Hengmo, PhD
Phone +8615810271669
Email ronghengmo@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic Obstructive Pulmonary Disease (COPD) is one of the top three causes of death worldwide now. Acute exacerbations (AEs) of COPD are a risk factor for lung function deterioration, poor quality of life, longer hospitalization, and increased mortality. To date, COPD is associated with a heavy clinical and socioeconomic burden, of which AEs of COPD account for a significant part of the cost of patients with COPD. Although several retrospective cohort studies and post-hoc analyses from randomized controlled trials (RCTs) showed that AECOPD patients with higher blood eosinophils had a shorter length of hospital stay (LOS), lower doses of corticosteroid use, and better response to systematic corticosteroid treatment than those with lower blood eosinophils, the efficacy of systematic corticosteroids in AECOPD patients with higher blood eosinophils has not been confirmed by RCTs. Therefore, this study aims to evaluate if AECOPD patients admitted to hospitals with higher blood eosinophil levels could benefit from systemic corticosteroid therapy. In this study, all eligible AECOPD participants with peripheral blood eosinophil blood count >2% or > 300 cells/μL will be randomly assigned (1:1) to either a control group or a systemic corticosteroid group. The control group will receive an oral placebo of 40mg/day for five consecutive days in addition to standard treatment during emergency admission or hospitalization. And systemic corticosteroid group will receive oral prednisone 40mg/day for five consecutive days and standard treatment. This study will provide evidence on using peripheral blood eosinophil blood count to guide corticosteroid therapy in AECOPD patients and help the clinician make an individual decision for each patient.


Description:

Data about individual deidentified participants of this trial will be available from the corresponding author Zhaohui Tong (Email: tongzhaohuicy@sina.com) on reasonable request after the main results of the ECHO study have been published.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 456
Est. completion date March 31, 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers No
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria: 1. Within 24 hours of admission; 2. Aged between of 40 and 80 years old; 3. Established clinical history of COPD with spirometry-verified COPD (defined as post-bronchodilator forced expiratory volume in one second (FEV1)/ forced vital capacity (FVC) = 0.70); 4. AECOPD diagnosis in accordance with the GOLD guideline (An acute worsening of respiratory symptoms that result in additional therapy)12; 5. Current or former cigarette smokers (=10 packs per year); 6. Blood eosinophil count > 2% or >300 cells/µL tested within 24 hours of admission; 7. Signed informed consent. Exclusion Criteria: 1. Admission due to other diseases (pneumonia, pneumothorax, pulmonary interstitial disease, active tuberculosis or bronchiectasis, ect); 2. Regular use of glucocorticoid =3 months; 3. Received prednisone = 60 mg in the past three days (or equivalent doses of other corticosteroid); 4. Allergic or intolerant to corticosteroid; 5. Participating in or completed another drug trial within 90 days; 6. Pregnancy or lactation; 7. Severe COPD exacerbation requiring invasive mechanical ventilation (IMV) or transfer to ICU within 24 hours after emergency admission or hospitalization; 8. With complications that may cause eosinophilia; 9. Pulmonary embolism within the past two years; 10. Myocardial infarction, uncontrollable congestive heart failure or arrhythmia within the past four weeks; 11. Comorbidity that may influence the immune system; 12. Malignant tumor; 13. Neuromuscular disease affecting the respiratory system; 14. Systemic fungal infection; 15. Thoracotomy or bronchoscopic lung volume reduction surgery history; 16. Adrenocortical insufficiency history; 17. Diabetes mellitus with poor glycemic control; 18. Uncontrollable severe psychiatric illnesses even with medication, cognitive impairment, and severe language difficulties; 19. ALT = 100U/L or AST = 80U/L; 20. Serum creatinine = 162umol/L; 21. Life expectancy of less than 30 days.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Prednisone
Oral prednisone 40mg/day for five consecutive days
Placebo
Oral placebo of 40mg/day for five consecutive days

Locations

Country Name City State
n/a

Sponsors (14)

Lead Sponsor Collaborator
Capital Medical University Beijing Anzhen Hospital, Beijing Jingmei Group Hospital, Beijing Jishuitan Hospital, Beijing Luhe Hospital, Beijing Shijingshan Hospital, Beijing Tongren Hospital, Beijing Yanhua Hospital, Bejing INFI-SAGACITY TECHNOLOGY CO., LTD, Chinese People's Liberation Army of China General Hospital, Emergency General Hospital, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Peking University, Xuanwu Hospital, Beijing

References & Publications (8)

Bafadhel M, Greening NJ, Harvey-Dunstan TC, Williams JE, Morgan MD, Brightling CE, Hussain SF, Pavord ID, Singh SJ, Steiner MC. Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. Chest. 2016 Aug;150(2):320-8. doi: 10.1016/j.chest.2016.01.026. Epub 2016 Feb 3. — View Citation

Cui Y, Zhan Z, Zeng Z, Huang K, Liang C, Mao X, Zhang Y, Ren X, Yang T, Chen Y. Blood Eosinophils and Clinical Outcomes in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Propensity Score Matching Analysis of Real-World Data in China. Front Med (Lausanne). 2021 Jun 9;8:653777. doi: 10.3389/fmed.2021.653777. eCollection 2021. — View Citation

Duffy SP, Criner GJ. Chronic Obstructive Pulmonary Disease: Evaluation and Management. Med Clin North Am. 2019 May;103(3):453-461. doi: 10.1016/j.mcna.2018.12.005. Epub 2019 Mar 14. — View Citation

Ko FWS, Chan KP, Ngai J, Ng SS, Yip WH, Ip A, Chan TO, Hui DSC. Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations. Respirology. 2020 Mar;25(3):259-266. doi: 10.1111/resp.13660. Epub 2019 Aug 6. — View Citation

Labaki WW, Rosenberg SR. Chronic Obstructive Pulmonary Disease. Ann Intern Med. 2020 Aug 4;173(3):ITC17-ITC32. doi: 10.7326/AITC202008040. — View Citation

Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418-22. doi: 10.1164/ajrccm.157.5.9709032. — View Citation

Sivapalan P, Lapperre TS, Janner J, Laub RR, Moberg M, Bech CS, Eklof J, Holm FS, Armbruster K, Sivapalan P, Mosbech C, Ali AKM, Seersholm N, Wilcke JT, Brondum E, Sonne TP, Ronholt F, Andreassen HF, Ulrik CS, Vestbo J, Jensen JS. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med. 2019 Aug;7(8):699-709. doi: 10.1016/S2213-2600(19)30176-6. Epub 2019 May 20. — View Citation

Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. Clin Chest Med. 2014 Mar;35(1):157-63. doi: 10.1016/j.ccm.2013.11.001. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment failure rates Collect during index hospitalization and within 30 days after discharge. Treatment failure is defined as either one of events: a) requiring or receiving invasive or non-invasive MV during the index hospitalization; b) requiring or transferring to ICU during the index hospitalization; c) length of index hospitalization longer than 14 days; d) death during the index hospitalization or within 30 days after discharge; e) readmission with acute exacerbations of COPD within 30 days after discharge. 30 days
Secondary Requiring or receiving invasive or non-invasive MV during the index hospitalization Collect during index hospitalization. 14 days
Secondary Requiring or transferring to ICU during the index hospitalization Collect during index hospitalization. 14 days
Secondary Length of index hospitalization longer than 14 days Collect during index hospitalization. 14 days
Secondary Death during the index hospitalization or within 30 days after discharge Collect during index hospitalization and 30-day follow-up. 30 days after discahrge
Secondary Readmission with acute exacerbations of COPD within 30 days after discharge Collect during index hospitalization and 30-day follow-up. 30 days after discahrge
Secondary All-cause mortality within 90 days after discharge Collect during 90-day follow-up. 90 days after discahrge
Secondary Readmission rates of AECOPD at 60-day and 90-day follow-ups Collect during 90-day follow-up. 90 days after discahrge
Secondary Time to readmission of AECOPD within 90 days after discharge Collect during 90-day follow-up. 90 days after discharge
Secondary Severer infection or development of pneumonia during hospitalization Collect during index hospitalization. 14 days
Secondary Changes in the scores of Hospital Anxiety and Depression Scale between index hospitalization and 90-day follow-up Collect during 90-day follow-up. The minimum and maximum values are 14 and 70, respectively. Higher scores mean a worse outcome. 90 days
Secondary Changes in the scores of St. George's Respiratory Questionnaire between index hospitalization and 90-day follow-up Collect during 90-day follow-up. The minimum and maximum values are 1 and 80, respectively. Higher scores mean a worse outcome. 90 days
Secondary Changes in the scores of exacerbations of chronic pulmonary disease tool between index hospitalization and 90-day follow-up Collect during huopitalization and 90-day follow-up. The minimum and maximum values are 14 and 73, respectively. Higher scores mean a worse outcome. 90 days
Secondary Changes in the scores of modified Medical Research Council Dyspnoea Scale between index hospitalization and 90-day follow-up Collect during huopitalization and 90-day follow-up. The minimum and maximum values are 1 and 5, respectively. Higher scores mean a worse outcome. 90 days
Secondary Changes in the scores of COPD Assessment Test between index hospitalization and 90-day follow-up Collect during huopitalization and 90-day follow-up. The minimum and maximum values are 0 and 40, respectively. Higher scores mean a worse outcome. 90 days
Secondary Changes in the scores of Transition Dyspnea Index between index hospitalization and 90-day follow-up Collect during huopitalization and 90-day follow-up. 90 days
Secondary Changes in the scores of COPD Exacerbation Recognition Tool during 90-day follow-up Collect during 90-day follow-up by patients. 90 days after discharge
Secondary Length of hospital stay during hospitalization Collect during huopitalization 14 days
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06000696 - Healthy at Home Pilot
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04105075 - COPD in Obese Patients
Recruiting NCT05825261 - Exploring Novel Biomarkers for Emphysema Detection
Active, not recruiting NCT04075331 - Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Phase 2/Phase 3
Terminated NCT03640260 - Respiratory Regulation With Biofeedback in COPD N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
Withdrawn NCT04210050 - Sleep Ventilation for Patients With Advanced Hypercapnic COPD N/A
Terminated NCT03284203 - Feasibility of At-Home Handheld Spirometry N/A
Recruiting NCT06110403 - Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness Phase 1/Phase 2
Active, not recruiting NCT06040424 - Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Recruiting NCT04868357 - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program N/A
Completed NCT01892566 - Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV N/A
Completed NCT04119856 - Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD N/A
Completed NCT04485741 - Strados System at Center of Excellence
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT04860375 - Multidisciplinary Management of Severe COPD N/A